Ripple Therapeutics Announces Evaluation and Licensing Agreements with Glaukos

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Ripple Therapeutics Corporation, a clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants, is pleased to announce evaluation and licensing agreements with Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal disease.

Ripple Therapeutics is an OBIO® member, an alumnus of our BDSP™, CAAP® and WiHI programs, and presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

Zucara Therapeutics Announces Strategic Investment from Sanofi as Part of US$20 M Series B Financing
Next

OBIO® and CATTI Collaborate to Boost Canada’s Biomanufacturing Capacity for Advanced Therapies